LVW Advisors LLC Acquires 944 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

LVW Advisors LLC lifted its holdings in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) by 13.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 7,798 shares of the medical device company’s stock after purchasing an additional 944 shares during the period. LVW Advisors LLC’s holdings in Tandem Diabetes Care were worth $281,000 as of its most recent filing with the SEC.

Several other institutional investors also recently modified their holdings of the business. Brooklyn Investment Group acquired a new position in Tandem Diabetes Care during the 3rd quarter worth about $28,000. Assetmark Inc. acquired a new position in shares of Tandem Diabetes Care in the third quarter worth approximately $29,000. ORG Wealth Partners LLC bought a new stake in Tandem Diabetes Care in the third quarter valued at approximately $30,000. Waldron Private Wealth LLC bought a new position in Tandem Diabetes Care during the 3rd quarter worth approximately $50,000. Finally, McIlrath & Eck LLC acquired a new position in shares of Tandem Diabetes Care in the 3rd quarter worth approximately $52,000.

Tandem Diabetes Care Price Performance

Shares of NASDAQ TNDM opened at $35.15 on Tuesday. The stock has a market cap of $2.31 billion, a price-to-earnings ratio of -18.21 and a beta of 1.29. The company has a debt-to-equity ratio of 1.29, a quick ratio of 2.32 and a current ratio of 2.90. Tandem Diabetes Care, Inc. has a fifty-two week low of $21.85 and a fifty-two week high of $53.69. The firm’s 50-day simple moving average is $33.64 and its 200 day simple moving average is $37.90.

Tandem Diabetes Care (NASDAQ:TNDM) last announced its earnings results on Wednesday, November 6th. The medical device company reported ($0.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.43) by $0.08. Tandem Diabetes Care had a negative return on equity of 44.19% and a negative net margin of 14.84%. The company had revenue of $243.97 million for the quarter, compared to analysts’ expectations of $224.14 million. During the same quarter in the previous year, the firm earned ($0.38) earnings per share. Tandem Diabetes Care’s quarterly revenue was up 31.4% on a year-over-year basis. As a group, research analysts anticipate that Tandem Diabetes Care, Inc. will post -1.68 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Kim D. Blickenstaff sold 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $30.00, for a total value of $300,000.00. Following the completion of the transaction, the director now directly owns 195,190 shares of the company’s stock, valued at $5,855,700. This represents a 4.87 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 2.20% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on TNDM shares. Morgan Stanley upgraded shares of Tandem Diabetes Care from an “equal weight” rating to an “overweight” rating and set a $45.00 price objective for the company in a research report on Monday, December 2nd. Citigroup decreased their price target on Tandem Diabetes Care from $57.00 to $50.00 and set a “buy” rating for the company in a report on Wednesday, December 11th. Robert W. Baird cut their target price on Tandem Diabetes Care from $39.00 to $37.00 and set a “neutral” rating on the stock in a research report on Thursday, November 7th. Sanford C. Bernstein started coverage on Tandem Diabetes Care in a research note on Wednesday, November 6th. They set an “outperform” rating and a $42.00 target price for the company. Finally, Barclays boosted their price target on Tandem Diabetes Care from $58.00 to $60.00 and gave the company an “overweight” rating in a research note on Friday, November 8th. Four equities research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $53.81.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.